Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.70 |
| ▸ | GSK3A | P49840 | 2/20 | 0.66 |
| ▸ | GSK3B | P49841 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40778 | 0.93 | CMA1 (0.66) | CMA1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL11684109 | 0.89 | MEN1 (0.62) | CMA1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL25339653 | 0.84 | GSK3A (0.59) | CMA1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL23120576 | 0.84 | MEN1 (0.61) | CMA1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL30100689 | 0.83 | POLB (0.71) | CMA1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL4328336 | 0.83 | POLB (0.71) | CMA1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL30100692 | 0.83 | POLB (0.71) | CMA1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL29173745 | 0.83 | CMA1 (0.54) | CMA1GSK3AGSK3BMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30616170 | 0.82 | MEN1 (0.59) | CMA1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL8117134 | 0.82 | CMA1 (0.77) | CMA1GSK3AGSK3BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62039565-A | — | — | None | — | — | JP | disclosed |
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-23 | — | — | US | disclosed |
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-23 | — | — | US | disclosed |
| US-11731116-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-08-22 | — | — | US | disclosed |
| US-11731116-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-08-22 | — | — | US | disclosed |
| EP-3919466-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | Yeda Research and Development Co. Ltd (IL) | 2021-12-08 | — | — | EP | disclosed |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| WO-2017137984-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-17 | — | — | WO | disclosed |
| CN-106604727-A | Compositions and methods to improve adoptive cell therapies | 7山利益有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| WO-2012002913-A1 | PROCESS OF FORMING A CYCLIC IMIDE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-01-05 | — | — | WO | disclosed |
| EP-0558630-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-04-08 | — | — | EP | disclosed |
| JP-S6239565-A | SUCCINIMIDE DERIVATIVE | OTA SEIYAKU KK | 1987-02-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CMA1 1689/4885GSK3A 2113/4885GSK3B 1987/4885 |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CMA1 1522/4885GSK3A 2073/4885GSK3B 1991/4885 |
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | ADH1C, OTC, MLEC | CMA1 1417/4885GSK3A 3883/4885GSK3B 4349/4885 |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CMA1 1689/4885GSK3A 2113/4885GSK3B 1987/4885 |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CMA1 1522/4885GSK3A 2073/4885GSK3B 1991/4885 |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CMA1 1706/4885GSK3A 1825/4885GSK3B 1744/4885 |
| US-11731116-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | ADH1C, OTC, ADH5 | CMA1 1459/4885GSK3A 4042/4885GSK3B 4423/4885 |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CMA1 1706/4885GSK3A 1825/4885GSK3B 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.